Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Nadine Mallak, Burcak Yilmaz, Catherine Meyer, Celeste Winters, Anna Mench, Abhinav Jha, Vikas Prasad, Erik Mittra

Research output: Contribution to journalArticlepeer-review

Abstract

Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.

Original languageEnglish
Article number101129
JournalCurrent Problems in Cancer
Volume52
DOIs
StatePublished - Oct 2024

Keywords

  • dosimetry
  • DOTATATE
  • NETs
  • somatostatin receptor
  • theranostics

Fingerprint

Dive into the research topics of 'Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies'. Together they form a unique fingerprint.

Cite this